AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver

Summary I rate AN2 Therapeutics a speculative buy, with a risk-adjusted base-case valuation of approximately $12 per share versus its September 18 closing price of $5.05. Epetraborole failed in treatment-refractory MAC lung disease, but its dose-dependent and reversible reductions in red-cell parameters could become therapeutic in polycythemia vera. Human and nonhuman-primate data support the erythroid effect, but EBO-PV-201 must demonstrate hematocrit control and reduced phlebotomy without causing clinically important anemia. Mimrylo, epetraborole’s prior efficacy and resistance history, licensing obligations, uncertain patent protection, and future dilution limit conviction, while the M. abscessus and Chagas programs provide additional optionality. spawns/E+ via Getty Images Investment Thesis I am giving AN2 Therapeutics ( ANTX ) a speculative Buy based on a failed drug. Let me explain my reasoning. Epetraborole is a boron-containing small molecule initially developed as an antibiotic. After it failed This article was written by Eljaye Tellis 9 Followers Follow Eljaye W. Tellis is a medicinal chemistry Ph.D. candidate and biotech investor. He covers biotechnology and healthcare equities, applying a therapeutic discovery and medicinal chemistry perspective to clinical-stage companies, catalysts, and valuation. His experience spans drug discovery, pharmaceutical development, translational research, and investment analysis. He has contributed to peer-reviewed scientific research as both a published co-author and through technical research contributions. His investment approach combines scientific diligence with fundamental analysis, focusing on drug mechanisms, clinical data, upcoming catalysts, competitive differentiation, and valuation. His goal is to translate complex drug-development science into accessible investment analysis and identify opportunities where the underlying science or clinical potential may be misunderstood or underappreciated by the market. Analyst’s Disclosure: I/we have a beneficial long position in the shares of ANTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.